ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

ARS Pharmaceuticals (Nasdaq: SPRY) announced that President and CEO Donn Casale will attend two September 2026 investor events: the Wells Fargo Healthcare Conference for 1x1 meetings on September 9 in Boston, and the Cantor Global Healthcare Conference, including a fireside chat on September 11 and 1x1 meetings September 10 in New York. A live and archived webcast of the Cantor fireside chat will be available for 30 days on the company’s website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences.

Wells Fargo Healthcare Conference

• 1x1 Investor Meetings: Wednesday, September 9, 2026
• Location: Boston

Cantor Global Healthcare Conference

• Fireside Chat: Friday, September 11, 2026, 8:35 a.m. ET
• 1x1 Investor Meetings: Thursday, September 10, 2026
• Location: New York
  

To access the live and archived webcast from the Cantor Global Healthcare Conference, please visit the Events & Presentations page in the “Investors & Media” section of the Company’s website. A replay will remain available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company developing and commercializing treatments that help at-risk patients and their caregivers treat and prevent severe allergic reactions. The company is commercializing neffy^® (epinephrine nasal spray), the only needle-free epinephrine approved by the U.S. Food & Drug Administration and European Medicines Agency, for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. (15kg) or more. The product is marketed as EURneffy^® in the European Union and as 优敏速^® in China. Leveraging its intranasal technology, ARS Pharma is also developing ARS-2, currently in a Phase 2b clinical trial, as a potential first treatment for acute flares of chronic spontaneous urticaria (CSU). For more information, visit www.ars-pharma.com and follow us on LinkedIn and X.

ARS Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com

ARS Media Contact:
Christy Curran, Sam Brown Inc.
615.414.8668
christycurran@sambrown.com

FAQ

When will ARS Pharmaceuticals (SPRY) present at the Wells Fargo Healthcare Conference 2026?

ARS Pharmaceuticals will participate in 1x1 investor meetings at the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, in Boston. According to ARS Pharmaceuticals, these meetings provide investors an opportunity to engage directly with management and discuss the company’s pipeline and commercial activities.

What is the date and time of ARS Pharmaceuticals (SPRY) fireside chat at the Cantor Global Healthcare Conference 2026?

ARS Pharmaceuticals’ fireside chat at the Cantor Global Healthcare Conference is scheduled for Friday, September 11, 2026, at 8:35 a.m. ET. According to ARS Pharmaceuticals, this session complements 1x1 investor meetings on September 10 in New York during the same conference.

How can investors access the ARS Pharmaceuticals (SPRY) Cantor Global Healthcare Conference 2026 webcast?

Investors can access the live and archived Cantor Global Healthcare Conference webcast via the Events & Presentations page in the Investors & Media section of ARS Pharmaceuticals’ website. According to ARS Pharmaceuticals, a replay will be available for 30 days following the event.

What does ARS Pharmaceuticals (SPRY) do and what is neffy?

ARS Pharmaceuticals is a biopharmaceutical company focused on treating and preventing severe allergic reactions. According to ARS Pharmaceuticals, it is commercializing neffy (epinephrine nasal spray), the only needle-free epinephrine approved by the FDA and EMA for emergency treatment of Type I allergic reactions, including anaphylaxis.

In which regions is ARS Pharmaceuticals’ neffy (SPRY) available and under what brand names?

According to ARS Pharmaceuticals, neffy (epinephrine nasal spray) is marketed as neffy in the United States, EURneffy in the European Union, and 优敏速 in China, targeting emergency treatment of Type I allergic reactions, including anaphylaxis, in eligible adults and children.

What is ARS-2 in the ARS Pharmaceuticals (SPRY) pipeline and what stage is it in?

ARS-2 is an intranasal product candidate that ARS Pharmaceuticals is developing for acute flares of chronic spontaneous urticaria (CSU). According to ARS Pharmaceuticals, ARS-2 is currently in a Phase 2b clinical trial as a potential first treatment option for these flares.